Security key
02043Q107
Alnylam Pharmaceuticals, Inc. - Common Stock (ALNY)
CUSIP: 02043Q107
Q3 2025 13F Holders as of 30 Sep 2025
- Security type / class
- Equity / Common Stock
- Total 13F shares
- 129,757,754
- Total 13F value
- $59,159,078,884
- Share change
- -2,388,462
- Put/Call ratio
- 116%
- SEC-reported price per share
- $456.00
- Number of holders
- 814
- Value change
- -$749,369,667
- Number of buys
- 496
- Number of sells
- 270
- Shares outstanding
- 133,985,952
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q3 2025
Institutions
814
Top holders
10
ALNY full security history
Ownership snapshot
Full 13F holder table
ALNYLAM PHARMACEUTICALS, INC. SEC filings
ALNYLAM PHARMACEUTICALS, INC. company facts
Broader feeds
Ownership snapshot
Top reported holders of ALNY - Alnylam Pharmaceuticals, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Capital World Investors
Disclosed value leader
Capital World Investors
Comparable rows
0/15
Latest evidence
30 Jun 2025
13F
Highest disclosed value: $5,479,867,052
15 rows are not safely comparable across share classes.
Showing 1-6 of 15 holder rows.
Quick read
Capital World Investors has the largest disclosed position value at $5.48B.
0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Capital World Investors's linked filing trail.
Disclosed position value
Top 5
Capital World Investors
$5.48B
FMR LLC
$5.15B
VANGUARD GROUP INC
$4.34B
BlackRock, Inc.
$3.25B
Capital Research Global Investors
$2.35B
Value bars compare disclosed positions; verify each figure against the linked filing evidence.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Capital World Investors |
13F
Company
|
—
denominator unverified
|
$5,479,867,052
16,805,007 shares
|
— | 30 Jun 2025 |
| FMR LLC |
13F
Company
|
—
denominator unverified
|
$5,154,348,251
15,806,521 shares
|
— | 30 Jun 2025 |
| VANGUARD GROUP INC |
13F
Company
|
—
denominator unverified
|
$4,336,064,057
13,297,139 shares
|
— | 30 Jun 2025 |
| BlackRock, Inc. |
13F
Company
|
—
denominator unverified
|
$3,254,431,218
9,980,163 shares
|
— | 30 Jun 2025 |
| Capital Research Global Investors |
13F
Company
|
—
denominator unverified
|
$2,345,092,829
7,191,656 shares
|
— | 30 Jun 2025 |
| REGENERON PHARMACEUTICALS, INC. |
13F
Company
|
—
denominator unverified
|
$1,449,289,070
4,444,445 shares
|
— | 30 Jun 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q3 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
814
Shares
129,757,754
Rows available
814
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q3 2025 vs Q2 2025 Across Filers
Q2 2025 holders
645
Q3 2025 holders
814
Holder diff
169
| Investor | Q2 2025 Shares | Q3 2025 Shares | Share Diff | Share Chg % | Q2 2025 value | Q3 2025 value | Value change | Value Chg % |
|---|